Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carfilzomib
Drug ID BADD_D00367
Description Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Indications and Usage Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.[L39392]
Marketing Status approved; investigational
ATC Code L01XG02
DrugBank ID DB08889
KEGG ID D08880
MeSH ID C524865
PubChem ID 11556711
TTD Drug ID D00UVA
NDC Product Code 76055-0035; 76075-103; 76075-101; 63552-009; 67262-0010; 42385-731; 76075-102; 63552-035; 54893-0037; 52076-6251; 55111-985; 11722-059
UNII 72X6E3J5AR
Synonyms carfilzomib | PR-171 | PR171 | Kyprolis
Chemical Information
Molecular Formula C40H57N5O7
CAS Registry Number 868540-17-4
SMILES CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3) NC(=O)CN4CCOCC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute lymphocytic leukaemia16.01.01.001; 01.10.01.0010.000112%Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.0010.000560%Not Available
Acute pulmonary oedema22.01.03.005; 02.05.02.0040.000560%Not Available
Acute respiratory distress syndrome24.03.02.034; 10.02.01.067; 22.01.03.0010.000336%
Ageusia17.02.07.001; 07.14.03.0030.000627%Not Available
Amyloidosis10.02.05.0010.000168%Not Available
Anaemia01.03.02.0010.003850%
Anaesthetic complication pulmonary12.02.20.004; 22.02.07.005--Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.000448%
Anxiety19.06.02.002--
Aortic stenosis24.04.01.0010.000168%Not Available
Aortic valve incompetence02.07.03.0010.000112%Not Available
Aphasia19.21.01.001; 17.02.03.0010.000604%
Aphonia19.19.01.002; 17.02.08.009; 22.12.03.0010.000381%
Arrhythmia02.03.02.0010.000839%Not Available
Arteriospasm coronary12.02.01.031; 24.04.04.005; 02.02.02.0050.000112%Not Available
Arthralgia15.01.02.001--
Arthropathy15.01.01.0030.000660%Not Available
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.0010.013443%Not Available
Atelectasis22.01.02.0010.000280%
Atrial fibrillation02.03.03.0020.001455%
Atrial flutter02.03.03.0030.000336%
Atrioventricular block02.03.01.0020.000224%Not Available
Atrioventricular block complete02.03.01.0030.000112%
Back disorder15.03.05.0030.000492%Not Available
Back pain15.03.04.0050.007544%
Blood creatinine increased13.13.01.004--
Blood pressure fluctuation24.06.01.0020.000571%Not Available
Body temperature increased13.15.01.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 12 Pages